NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note released on Monday morning. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.60 on Monday. The firm has a market capitalization of $3.46 million, a PE ratio of -0.01 and a beta of 0.42. The company’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $0.62. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08.

Insider Buying and Selling at NovaBay Pharmaceuticals

In other news, major shareholder Poplar Point Capital Partners bought 49,400 shares of the stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $0.61 per share, with a total value of $30,134.00. Following the acquisition, the insider now owns 950,000 shares in the company, valued at $579,500. This trade represents a 5.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 196,092 shares of company stock valued at $119,495 in the last 90 days. 0.10% of the stock is currently owned by company insiders.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.